Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 12/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22526354 | 1.00 | PIK3CD (0.42) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL23842181 | 1.00 | PIK3CD (0.42) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL23806884 | 0.90 | EPHX1 (0.41) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL23807050 | 0.90 | EPHX1 (0.41) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL22856545 | 0.88 | PIK3CD (0.43) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL23696544 | 0.88 | PIK3CD (0.43) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL23518626 | 0.88 | PIK3CD (0.43) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL9921758 | 0.86 | PIK3CD (0.44) | PIK3CDDRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL24508486 | 0.85 | PIK3CD (0.36) | PIK3CDDRD4DRD3DRD2CYP1A2 | |
| SCHEMBL25468987 | 0.83 | PIK3CD (0.37) | PIK3CDDRD4DRD3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885DRD4 4363/4885DRD3 4304/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885DRD4 4363/4885DRD3 4304/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | PIK3CD 335/4885DRD4 3821/4885DRD3 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.